-
Rituximab in MS Seen to Affect How B-cells Return After Treatment Stops
A study in 15 patients using rituximab, a B-cell depletion therapy targeting CD20, found B-cells that return after use stops were less mature. Click here to learn more.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.